Solid Biosciences SLDB Stock
Solid Biosciences Price Chart
Solid Biosciences SLDB Financial and Trading Overview
| Solid Biosciences stock price | 10.37 USD |
| Previous Close | 6.12 USD |
| Open | 6.11 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 900 |
| Day's Range | 6 - 6.26 USD |
| 52 Week Range | 3.4 - 14.25 USD |
| Volume | 9.5K USD |
| Avg. Volume | 37.36K USD |
| Market Cap | 122.71M USD |
| Beta (5Y Monthly) | 1.426408 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.83 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.33 USD |
SLDB Valuation Measures
| Enterprise Value | -38176580 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.6827958 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 19.890646 |
| Price/Book (mrq) | 0.6666667 |
| Enterprise Value/Revenue | -6.188 |
| Enterprise Value/EBITDA | 0.369 |
Trading Information
Solid Biosciences Stock Price History
| Beta (5Y Monthly) | 1.426408 |
| 52-Week Change | -27.79% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 14.25 USD |
| 52 Week Low | 3.4 USD |
| 50-Day Moving Average | 5.65 USD |
| 200-Day Moving Average | 6.41 USD |
SLDB Share Statistics
| Avg. Volume (3 month) | 37.36K USD |
| Avg. Daily Volume (10-Days) | 55.69K USD |
| Shares Outstanding | 19.6M |
| Float | 7.42M |
| Short Ratio | 1.66 |
| % Held by Insiders | 0.41% |
| % Held by Institutions | 78.37% |
| Shares Short | 25.53K |
| Short % of Float | 0.27% |
| Short % of Shares Outstanding | 0.13% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1717.16% |
| Gross Margin | 104.57% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.29% |
| Return on Equity (ttm) | -49.13% |
Income Statement
| Revenue (ttm) | 6.17M USD |
| Revenue Per Share (ttm) | 0.54 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -103530000 USD |
| Net Income Avi to Common (ttm) | -90723000 USD |
| Diluted EPS (ttm) | -8.09 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 185.51M USD |
| Total Cash Per Share (mrq) | 9.46 USD |
| Total Debt (mrq) | 27.37M USD |
| Total Debt/Equity (mrq) | 14.89 USD |
| Current Ratio (mrq) | 9.393 |
| Book Value Per Share (mrq) | 9.39 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -98782000 USD |
| Levered Free Cash Flow (ttm) | -48727500 USD |
Profile of Solid Biosciences
| Country | United States |
| State | MA |
| City | Charlestown |
| Address | 500 Rutherford Avenue |
| ZIP | 02129 |
| Phone | 617 337 4680 |
| Website | https://www.solidbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 87 |
Solid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Q&A For Solid Biosciences Stock
What is a current SLDB stock price?
Solid Biosciences SLDB stock price today per share is 10.37 USD.
How to purchase Solid Biosciences stock?
You can buy SLDB shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Solid Biosciences?
The stock symbol or ticker of Solid Biosciences is SLDB.
Which industry does the Solid Biosciences company belong to?
The Solid Biosciences industry is Biotechnology.
How many shares does Solid Biosciences have in circulation?
The max supply of Solid Biosciences shares is 37.76M.
What is Solid Biosciences Price to Earnings Ratio (PE Ratio)?
Solid Biosciences PE Ratio is now.
What was Solid Biosciences earnings per share over the trailing 12 months (TTM)?
Solid Biosciences EPS is -4.83 USD over the trailing 12 months.
Which sector does the Solid Biosciences company belong to?
The Solid Biosciences sector is Healthcare.
Solid Biosciences SLDB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
- {{ link.label }} {{link}}